


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 1 of 1

Complete if Known

Application Number	10/081,050
Filing Date	February 20, 2002
First Named Inventor	Osborne, David
Group Art Unit	1615
Examiner Name	Channavajjala, Lakshmi

Attorney Docket No: 1195.346US1

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
<input checked="" type="checkbox"/>	US-4,829,058	05/09/1989	Seydel, Joachim K., et al.	06/15/1987
<input checked="" type="checkbox"/>	US-4,912,112	03/27/1990	Seydel, Joachim, et al.	02/06/1987
<input checked="" type="checkbox"/>	US-5,733,572	03/31/1998	Unger, Evan C., et al.	11/29/1994
<input checked="" type="checkbox"/>	US-6,056,955	05/02/2000	Fischetti, V., et al.	09/14/1999
<input checked="" type="checkbox"/>	US-6,248,324	06/19/2001	Fischetti, Vincent, et al.	09/28/2000
<input checked="" type="checkbox"/>	US-6,254,866	07/03/2001	Fischetti, Vincent, et al.	09/01/2000
<input checked="" type="checkbox"/>	US-6,277,399	08/21/2001	Fischetti, Vincent, et al.	09/28/2000

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
--------------------	---------------------	------------------	---	----------------

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<input checked="" type="checkbox"/>		COLEMAN, MICHAEL D., et al., "Preliminary evaluation of the toxicity and efficacy of novel 2,4-diamino-5-benzylpyrimidine-sulphone derivatives using rat and human tissues in vitro", <u>Environmental Toxicology and Pharmacology</u> , 2(4), (December 20, 1996), 389-395	
<input checked="" type="checkbox"/>		COLEMAN, MICHAEL D., et al., "Studies on the inhibitory effects of analogues of dapsone on neutrophil function in vitro", <u>J. Pharm. Pharmacol.</u> 49(1), (January 1997), 53-57	
<input checked="" type="checkbox"/>		COLEMAN, MICHAEL D., et al., "Studies on the toxicity of analogues of dapsone in-vitro using rat, human and heterologously expressed metabolizing systems", <u>J. Pharm. Pharmacol.</u> , 48(9), (September 1996), 945-950	

EXAMINER

L. Channavajjala

DATE CONSIDERED

6/15/05

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached